BioWorld Asia

March 14, 2007

Oxford BioMedica Buys Oxxon, In Share Offering Valued At £16M

LONDON - Oxford BioMedica plc is acquiring its fellow immunotherapy specialist Oxxon Therapeutics Ltd. in an all-paper deal that values Oxxon at £12 million (US$23.3 million). In addition to six clinical stage products, the deal brings Oxford BioMedica £3 million in cash. (BioWorld International) Read More

Early Data Open New Market For AM-Pharma's Lead Drug

Protein Fragment Offers Hope For New Cancer-Killing Agent

EU Battle Lines Harden As Biotech Manifesto' Sent Back

BioAlliance, Spepharm Partner In Deal To Market Loramyc

NovaThera Expanded Deal Moves Toward Artificial Lung

Transgene Reports Net '06 Loss But Expects Busy Year Ahead

TopoTarget In-Licenses Novartis Antibody Fragment For Cancer

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 18, 2025.

Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

HIV research is close to a cure but far from ending the pandemic

BioWorld

Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 18, 2025.

Maintenance, man: Lilly’s phase III weight trial hits goals

BioWorld

Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...

Insilico CEO Alex Zhavoronkov and the automated lab’s humanoid that runs all preclinical tests in the Hong Kong lab.

AI drug developer Insilico to raise $292 million in Hong Kong IPO

BioWorld

Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to advance its clinical pipeline and invest...